Clinical trial
A Prospective Multicenter Post Market Trial to Assess the Safety and Effectiveness of the Firehawk™ Rapamycin Target Eluting Cobalt Chromium Coronary Stent System (Firehawk™ Stent System) for the Treatment of Atherosclerotic Lesion(s)
NCT02520180 is registered in ClinicalTrials.gov with Shanghai MicroPort Medical (Group) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Multicenter Post Market Trial to Assess the Safety and Effectiveness of the Firehawk™ Rapamycin Target Eluting Cobalt Chromium Coronary Stent System (Firehawk™ Stent System) for the Treatment of Atherosclerotic Lesion(s)
- Lead sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- December 31, 2015
- Completion date
- June 30, 2022
- Enrollment
- 1,653 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.